Hb H disease and multiple myeloma.
Elhajj
Ihab
I
Department of Internal Medicine, Division of Hematology-Oncology, American University of Beirut, Beirut, Lebanon.
Chehal
Aref
A
Shamseddine
Ali
A
Mourad
Yasser Abou
YA
Taher
Ali
A
D000368:Aged; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008558:Melphalan / Q000627:therapeutic use*; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000209:etiology; D011241:Prednisone / Q000627:therapeutic use*; D013156:Splenectomy; D013792:Thalidomide / Q000627:therapeutic use*; D017085:alpha-Thalassemia / Q000150:complications / Q000188:drug therapy* / Q000601:surgery
D000893:Anti-Inflammatory Agents; D018906:Antineoplastic Agents, Alkylating; D007166:Immunosuppressive Agents; D013792:Thalidomide; D008558:Melphalan; D011241:Prednisone